Search Within

Lorenzo Falchi

Formats
  1. Meeting Abstract (96)
  2. Journal Article (23)
  3. Research Letter (6)
  4. Review (5)
  5. Correspondence (2)
  6. Editorial (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (134)
  2. Hematologic Malignancies, Division of (134)
  3. Center for Hematologic Malignancies (88)
  4. Lymphoma (78)
  5. Sloan Kettering Institute Postdocs (57)
  6. Survivorship Research (54)

More Groups

People
  1. Gilles Salles (66)
  2. Andrew Zelenetz (64)
  3. Maria Palomba (63)
  4. Anita Kumar (61)
  5. Ariela Noy (57)
  6. Alison Moskowitz (54)

More People

Years
  1. 2025 (8)
  2. 2024 (40)
  3. 2023 (43)
  4. 2022 (23)
  5. 2021 (14)
  6. 2020 (6)
Publications
  1. Blood (67)
  2. Journal of Clinical Oncology (11)
  3. Hematological Oncology (9)
  4. Blood Advances (5)
  5. Clinical Lymphoma, Myeloma and Leukemia (5)
  6. Leukemia and Lymphoma (5)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. American Society of Clinical Oncology (11)
  3. Wiley Blackwell (9)
  4. Elsevier Inc. (8)
  5. Taylor & Francis Group (5)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (134)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diagnostic discrepancies in small-volume biopsy for the initial diagnosis, recurrence, and transformation of follicular lymphoma: A multi-institutional collaborative study
    Journal Article

    Volaric, A. K.; Lin, O.; Balassanian, R.; Cook, S.; Falchi, L.; Fitzpatrick, M. J.; Frank, A. K.; Gupta, S.; Hasserjian, R. P.; Long, S.; more...
    American Journal of Surgical Pathology (2023)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab with rituximab + lenalidomide (R(2)) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial
    Meeting Abstract

    Falchi, L.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; De Vos, S.; Holte, H.; Linton, K. M.; Abbas, A.; Wang, L. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • First-line treatment with subcutaneous epcoritamab plus R-CHOP in patients with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update
    Meeting Abstract

    Falchi, L.; Offner, F.; Belada, D.; Brody, J.; Linton, K. M.; Karimi, Y.; Cordoba, R.; Snauwaert, S.; Abbas, A.; Wang, L. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase 3 trial of subcutaneous epcoritamab in combination with rituximab and lenalidomide (R(2)) vs R(2) among patients with relapsed or refractory follicular lymphoma (EPCORE FL-1)
    Meeting Abstract

    Falchi, L.; Morschhauser, F.; Gribben, J. G.; Huang, H.; Dinh, M.; Conlon, R.; Chen, X.; Elliot, B.; Seymour, J. F.
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab in combination with rituximab + lenalidomide (R(2)) for first-line treatment of follicular lymphoma: Initial results from phase 1/2 trial
    Meeting Abstract

    Falchi, L.; Leslie, L. A.; Belada, D.; Kopeckova, K.; Offner, F.; Brody, J.; Canales, M.; García-Sancho, A. M.; Nijland, M.; Andersson, P. O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update
    Meeting Abstract

    Falchi, L.; Abrisqueta, P.; Nijland, M.; Leppä, S.; Hutchings, M.; Holte, H.; Merryman, R. W.; Lugtenburg, P.; de Vos, S.; Cheah, C. Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab + R-DHAX/C in patients with relapsed or refractory diffuse large B-cell lymphoma eligible for autologous stem cell transplant: Updated phase 1/2 results
    Meeting Abstract

    Abrisqueta, P.; Cordoba, R.; Falchi, L.; de Vos, S.; Nijland, M.; Offner, F.; Wu, J.; Bykhovski, I.; Wang, L.; Rana, A.; more...
    Blood (2022)

    Fulltext@MSK | Save